Opinion
Video
Author(s):
The panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.
UGN-101 demonstrates long-term durability in low-grade UTUC
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC
Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
Expert roundtables focus on upper tract urothelial carcinoma
Study to assess performance of CxBladder test in urothelial carcinoma surveillance